CommercialCoverageMedium impact
08.00.33w, Trastuzumab (Herceptin®) and Related Biosimilars, Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 20, 2026
We identified it
Jun 19, 2026
Summary
Updated medical necessity criteria and coding guidelines for Trastuzumab (Herceptin®) and related biosimilars, including Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta). This affects coverage determination and billing requirements for these cancer treatment medications.
Action Required
Before April 20, 2026: Billing team must review updated medical necessity criteria for Trastuzumab and related biosimilars. Update prior authorization workflows and documentation requirements. Providers should ensure medical necessity documentation aligns with new criteria before submitting claims.